Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer

March 26th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

ASCO and ESMO Value Frameworks May Be Beneficial in Determining Best Maintenance Therapies for Ovarian Cancer

March 26th 2018

To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.

Dr. Mirza Discusses Niraparib Dose Modifications for Patients With Low Body Weight

March 26th 2018

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.

Low Body Weight, Platelet Counts Predict Niraparib Dose Reductions for Ovarian Cancer

March 25th 2018

Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Monk on Choosing Between PARP Inhibitors in Ovarian Cancer

March 25th 2018

Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.

Checkpoint Inhibitors Induce Higher Rate of Adverse Events in Recurrent Ovarian Cancer

March 25th 2018

The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.

Dr. Backes Discusses PARP Inhibitor Combinations in Ovarian Cancer

March 23rd 2018

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. O'Malley Discusses PARP Combinations in Ovarian Cancer

March 19th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in ovarian cancer.

Dr. Moore on Challenges With Immunotherapy in Ovarian Cancer

March 16th 2018

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses challenges with immunotherapy agents in the treatment of patients with ovarian cancer.

Dr. Crane on the Toxicity Profile of Combinations for Ovarian Cancer

March 13th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the toxicity profile of combination regimens for patients with ovarian cancer.

Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian Cancer

March 9th 2018

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.

Dr. O'Malley on the Tolerability of PARP Inhibitors in Ovarian Cancer

February 28th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the tolerability of PARP inhibitors for patients with ovarian cancer.

Is the Median All We Should Offer Our Patients?

February 28th 2018

Although median survival is a reasonable endpoint to highlight, it is only 1 of many relevant outcome factors to discuss, and, most important, this mathematical figure simply does not define the survival of any particular patient.

EU Panel Recommends Olaparib Tablets for Ovarian Cancer, Regardless of BRCA Status

February 24th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Moore Discusses Combinations in Ovarian Cancer

February 23rd 2018

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

Dr. Crane on Combinations With PARP Inhibitors in Ovarian Cancer

February 17th 2018

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses combinations with PARP inhibitors in ovarian cancer.

Dr. O'Malley Discusses the Current Role of PARP Inhibitors in Ovarian Cancer

February 14th 2018

David O'Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the current role for PARP inhibitors for patients with ovarian cancer.

Immunotherapy Combos on Horizon for Ovarian Cancer

February 11th 2018

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.

PARP Combinations Offer New Opportunities in Ovarian Cancer

February 11th 2018

PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.

Dr. Arend on the Rationale of Novel Combinations in Gynecologic Cancer

February 10th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.